The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials

scientific article published on June 2008

The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1158/1078-0432.CCR-07-4559
P698PubMed publication ID18559580
P5875ResearchGate publication ID5296314

P2093author name stringRuth Plummer
A Hilary Calvert
P433issue12
P407language of work or nameEnglishQ1860
P921main subjectpharmacokineticsQ323936
pharmacodynamicsQ725307
phase I clinical trialQ5452194
P304page(s)3664-3669
P577publication date2008-06-01
P1433published inClinical Cancer ResearchQ332253
P1476titleThe development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials
P478volume14

Reverse relations

cites work (P2860)
Q33408198Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.
Q52151988Brain Tumor Clinical Trials: Perspective 2014.
Q36732115Designing phase 0 cancer clinical trials
Q41896620Early human studies of investigational agents: dose or microdose?
Q38700689Embracing model-based designs for dose-finding trials.
Q39010445FGFR-TACC gene fusions in human glioma
Q35940544Microdosing and drug development: past, present and future
Q36732058Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient
Q38818203Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development
Q35602195Phase 0 Workshop at the 20th EORTC-NCI-AACR Symposium, Geneva.
Q34941964Phase 0 clinical trials in oncology new drug development
Q36795347Principles of dose finding studies in cancer: a comparison of trial designs.
Q37367075Retinoid chemoprevention trials: cyclin D1 in the crosshairs
Q39934032Role of Phase 0 trials in drug development
Q35146271The histone methyltransferase SMYD2 methylates PARP1 and promotes poly(ADP-ribosyl)ation activity in cancer cells
Q33775647What are the endpoints of therapy for acute leukemias? Old definitions and new challenges

Search more.